Anxiety, Depression Higher, QOL Lower Between Chemotherapy Cycles for Breast Cancer
A longitudinal study assessed psychological status of postoperative patients with breast cancer between adjuvant chemotherapy for anxiety and depression.
A longitudinal study assessed psychological status of postoperative patients with breast cancer between adjuvant chemotherapy for anxiety and depression.
Results of a recent study found that the effectiveness of the 9-item Patient Health Questionnaire (PHQ-9) and the Hospital Anxiety and Depression Scale (HADS-D) in screening for major depressive disorder (MDD) in patients with cancer was limited compared to the standardized diagnostic interview.
Participants with high risk of depression reported lower mood disturbance, anxiety, depression following intervention.
Called CALM, the psychological intervention tries to help patients live with their disease rather than just prepare them for the end of life.
Temozolomide, an antimitotic chemotherapy used to treat brain cancer, demonstrated the potential to increase depression in a mouse model.
In this study, researchers measured the psychological manifestations among patients with BCR-ABL-negative MPNs to determine the effects of anxiety, distress, and depression on symptom burden in this patient population.
An assessment of depression in patients before autologous or allogeneic HCT demonstrated that the condition impacts overall survival and risk of GVDH in patients with hematologic malignancies.
New evidence indicates that depression can impact cancer outcomes following chemotherapy.
An analysis of data from Danish women with early-stage breast cancer assessed women’s risk of receiving nonguideline treatment for their disease if they had a prior diagnosis of depression or prior treatment with antidepressants.
Nearly one in five cancer survivors are taking medication for depression or anxiety years later.